Barinthus Biotherapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on the stock and has a $4.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Yi Chen has given his Buy rating due to a combination of factors surrounding Barinthus Biotherapeutics’ promising developments in their clinical trials and strategic business moves. The company reported positive results from the single ascending dose (SAD) portion of their Phase 1 AVALON trial for VTP-1000, a treatment for celiac disease. The trial showed that VTP-1000 was well tolerated across all dose levels without any treatment-related serious adverse events, and demonstrated a dose-dependent pharmacological effect. This suggests a promising outlook for the upcoming multiple ascending dose (MAD) portion of the trial, with data expected in the second half of 2026.
Additionally, Barinthus Biotherapeutics is set to merge with Clywedog Therapeutics, which is anticipated to close in the first half of 2026. This merger is expected to enhance the company’s portfolio with assets targeting metabolic and autoimmune diseases, including promising treatments for Type 1 and Type 2 diabetes. The merger and the ongoing development of these assets position the company well for future growth, supporting the Buy rating and a price target of $4.